PL1855661T3 - Preparaty zawierające awiptadil - Google Patents

Preparaty zawierające awiptadil

Info

Publication number
PL1855661T3
PL1855661T3 PL06707454T PL06707454T PL1855661T3 PL 1855661 T3 PL1855661 T3 PL 1855661T3 PL 06707454 T PL06707454 T PL 06707454T PL 06707454 T PL06707454 T PL 06707454T PL 1855661 T3 PL1855661 T3 PL 1855661T3
Authority
PL
Poland
Prior art keywords
aviptadil
formulation
Prior art date
Application number
PL06707454T
Other languages
English (en)
Inventor
Gerald Bacher
Dorian Bevec
Original Assignee
Mondobiotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Ag filed Critical Mondobiotech Ag
Publication of PL1855661T3 publication Critical patent/PL1855661T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
PL06707454T 2005-03-07 2006-03-07 Preparaty zawierające awiptadil PL1855661T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102005010415 2005-03-07
US66282105P 2005-03-18 2005-03-18
EP06707454A EP1855661B1 (en) 2005-03-07 2006-03-07 Formulation for aviptadil
PCT/EP2006/002084 WO2006094764A1 (en) 2005-03-07 2006-03-07 Formulation for aviptadil

Publications (1)

Publication Number Publication Date
PL1855661T3 true PL1855661T3 (pl) 2011-10-31

Family

ID=36354043

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06707454T PL1855661T3 (pl) 2005-03-07 2006-03-07 Preparaty zawierające awiptadil

Country Status (10)

Country Link
US (1) US8178489B2 (pl)
EP (1) EP1855661B1 (pl)
JP (1) JP2008537542A (pl)
AU (1) AU2006222233B2 (pl)
CA (1) CA2601279A1 (pl)
ES (1) ES2363738T3 (pl)
MX (1) MX2007010930A (pl)
NZ (1) NZ560648A (pl)
PL (1) PL1855661T3 (pl)
WO (1) WO2006094764A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
WO2009033714A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
ES2531657T3 (es) * 2008-05-01 2015-03-18 Arecor Limited Formulación de una proteína
CN102361632A (zh) * 2009-03-30 2012-02-22 弗·哈夫曼-拉罗切有限公司 避免玻璃雾化的方法
CN103159845B (zh) * 2013-03-26 2015-03-18 深圳翰宇药业股份有限公司 一种合成阿肽地尔的方法
CN104447963B (zh) * 2014-11-14 2017-11-07 杭州阿诺生物医药科技股份有限公司 一种制备阿肽地尔的方法
WO2022119535A1 (en) 2020-12-04 2022-06-09 Centurion Ilac Sanayi Ve Ticaret Anonim Sirketi New dosage regimen for inhaled vasoactive intestinal polypeptide
TR2022010940A2 (tr) * 2022-07-01 2024-01-22 Centurion Ilac Sanayi Ve Ticaret Anonim Sirketi Avi̇ptadi̇l sivi formülasyon üreti̇m yöntemi̇.
WO2024095157A1 (en) * 2022-11-02 2024-05-10 Relief Therapeutics International Sa Stable aviptadil formulations
DE102025003291A1 (de) * 2025-01-02 2026-07-02 ReViSan Healthcare GmbH Verfahren und Zubereitung zur Behandlung von entzündlichen Erkrankungen der Atemwege bei Pferden durch inhalative Therapie mit Aviptadil.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3898329A (en) * 1971-09-17 1975-08-05 Sami I Said Vasoactive intestinal peptide, composition and method
US4016258A (en) * 1975-08-05 1977-04-05 Said Sami I Vasoactive intestinal peptide from fowl
US4237046A (en) * 1979-04-27 1980-12-02 Miklos Bodanszky Polypeptides and methods of preparation
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5236904A (en) 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
DK0463450T3 (da) * 1990-06-26 1994-06-27 Sanwa Kagaku Kenkyusho Co Vasoaktive intestinale polypeptid-analoger og udnyttelsen heraf
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
US5958881A (en) * 1991-04-25 1999-09-28 Korman; Louis Y. Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures
US5681816A (en) 1992-04-24 1997-10-28 Korman; Louis Y. Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure
AU2249701A (en) 1999-11-12 2001-06-06 David Bernstein Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use
KR20040065212A (ko) * 2001-11-06 2004-07-21 센주 세이야꾸 가부시키가이샤 건조안 및 건조안과 연관된 질환의 치료제
EP1530588A2 (en) * 2002-07-31 2005-05-18 Conjuchem, Inc. Long lasting natriuretic peptide derivatives
CN100381462C (zh) * 2002-11-27 2008-04-16 伊藤火腿株式会社 肽及含有所述肽的药物组合物

Also Published As

Publication number Publication date
NZ560648A (en) 2010-03-26
ES2363738T3 (es) 2011-08-12
MX2007010930A (es) 2008-03-14
WO2006094764A1 (en) 2006-09-14
AU2006222233B2 (en) 2011-05-12
US20080161237A1 (en) 2008-07-03
EP1855661B1 (en) 2011-05-04
CA2601279A1 (en) 2006-09-14
AU2006222233A1 (en) 2006-09-14
EP1855661A1 (en) 2007-11-21
JP2008537542A (ja) 2008-09-18
US8178489B2 (en) 2012-05-15

Similar Documents

Publication Publication Date Title
GB2424581B (en) Formulations
ZA200801773B (en) New formulation
PL2526930T3 (pl) Formulacja witaminowa
PL1879451T3 (pl) Innowacyjna formulacja
GB0518783D0 (en) Indolizine compounds
ZA200802602B (en) Controlled release formulation
GB0608098D0 (en) Formulation
ZA200707654B (en) Formulations
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
TWI370115B (en) New formulation
GB0423565D0 (en) Formulation
GB0507208D0 (en) Anti-inflammatory formulation
GB0526419D0 (en) Formulation
GB0412530D0 (en) Formulation
GB0517673D0 (en) Formulation
EP1928469A4 (en) Fulvestrant FORMULATION
ZA200802953B (en) Solid vaccine formulation
GB0625095D0 (en) Formulation
GB0625312D0 (en) Formulation
ZA200803086B (en) Bisphosphonate formulation
PT1855661E (pt) Formulações para aviptadil
GB0501030D0 (en) Formulation
GB0612809D0 (en) Formulation
LT1928232T (lt) Kieta kompozicija
GB0500071D0 (en) Cleaning formulation